10-Q: Nexalin Technology Reports Third Quarter 2024 Results, Navigates Regulatory and Financial Challenges

Nexalin Technology's Q3 2024 report reveals increased revenue but ongoing losses, alongside efforts to navigate regulatory hurdles and maintain Nasdaq listing compliance.

Summary

• Nexalin Technology reported a net loss of $2.45 million for the third quarter of 2024, compared to a net loss of $2.30 million for the same period in 2023.
• The company's revenue increased to $36,031 in Q3 2024 from $24,113 in Q3 2023, primarily due to increased sales of supplies and parts.
• Operating expenses totaled $2.53 million for Q3 2024, compared to $2.44 million in Q3 2023, with increases in professional fees and stock compensation offset by decreases in salaries and research and development costs.
• For the nine months ended September 30, 2024, Nexalin's net loss was $4.77 million, compared to $3.87 million for the same period in 2023.
• Revenue for the first nine months of 2024 was $141,542, up from $90,212 in the same period of 2023, driven by device sales to a new overseas customer.
• The company's operating expenses for the first nine months of 2024 were $4.99 million, compared to $4.14 million in 2023, with increases in shareholder expenses, travel, and stock compensation offset by decreases in research and development costs.
• Nexalin had a working capital surplus of approximately $4.6 million as of September 30, 2024, but its operating activities consume most of its cash resources.
• The company is working to obtain FDA clearance for its Gen-3 device and is also pursuing a PMA application for the treatment of depression.
• Nexalin is also navigating Nasdaq listing requirements, including maintaining a minimum bid price and stockholders' equity.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is positive revenue growth and strategic initiatives, the significant net losses, ongoing regulatory hurdles, and financial uncertainties create a negative sentiment overall. The company's dependence on future capital raises and the material weaknesses in internal controls are also concerning.

Positives

• The company experienced a significant increase in revenue for both the quarter and the first nine months of 2024.
• Gross profit increased for both the quarter and the first nine months of 2024.
• The company has a joint venture in China, which has already received regulatory approval for the Gen-2 device.
• Nexalin has received regulatory approvals in Oman and Brazil, expanding its market reach.
• The company is developing a virtual clinic platform, which could improve patient access and reduce stigma.
• Nexalin has regained compliance with Nasdaq's minimum bid price and stockholder equity requirements.
• The company successfully raised capital through a public offering in July 2024.

Negatives

• The company continues to experience significant net losses.
• Operating expenses remain high, offsetting revenue gains.
• The company's operating activities consume most of its cash resources.
• There is uncertainty regarding the timing and cost of completing clinical development and obtaining regulatory approvals.
• The company is dependent on its ability to raise additional capital to continue as a going concern.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company is subject to ongoing risks related to its joint venture in China.

Risks

• The company's ability to continue as a going concern is dependent on its ability to generate revenue and raise additional capital.
• There is uncertainty regarding the timing and outcome of FDA regulatory approvals for the company's devices.
• The company faces risks related to its joint venture in China, including economic, political, and legal uncertainties.
• The company is subject to ongoing litigation and regulatory matters.
• The company's intellectual property rights may be difficult to enforce in China.
• The company is dependent on a small number of customers for a significant portion of its revenue.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company is subject to the risk of not maintaining compliance with Nasdaq listing requirements.

Future Outlook

The company expects to continue to incur operating losses as it executes its development plans and pursues strategic initiatives. The company's ability to continue as a going concern is dependent on its ability to generate revenue, obtain regulatory approvals, and raise additional capital.

Management Comments

• The Nexalin research team believes that the new 15 milliamp Gen-2 and Gen-3 devices can penetrate deeper into the brain and stimulate associated structures of mental illness, which we believe will generate enhanced patient response without any risk or unpleasant side effects.
• Our mission is to remove the stigma of expensive psychotherapy or pharmaceuticals with the attendant side effects and dependency issues and replace such stigma with clinically proven and cost-effective technology that is easily accessible in the privacy of the patients home and monitored by licensed healthcare providers.
• Management has evaluated the significance of the conditions as of September 30, 2024 and have concluded that we will not have sufficient cash and short-term investments to satisfy our anticipated cash requirements for the next twelve months from the issuance of these financial statements.

Industry Context

The company operates in the neurostimulation market, which is experiencing growth due to the increasing prevalence of mental health disorders. The company's focus on non-invasive treatments and its virtual clinic platform align with current trends in healthcare. The company faces competition from established medical device companies and pharmaceutical companies.

Comparison to Industry Standards

• Nexalin's revenue growth of 57% for the first nine months of 2024 is significant compared to the average growth rate in the medical device industry, which is typically in the single-digit to low double-digit range.
• However, Nexalin's continued net losses are a concern, as many medical device companies aim for profitability within a few years of commercialization.
• The company's reliance on a small number of customers for a large portion of its revenue is a risk, as it is not in line with industry best practices of diversifying revenue streams.
• The company's focus on a virtual clinic platform is innovative and could provide a competitive advantage, as telehealth is a growing trend in healthcare.
• Compared to companies like NeuroMetrix and Neuronetics, which also focus on neurostimulation, Nexalin is still in an earlier stage of commercialization and faces greater regulatory and financial challenges.
• The company's joint venture in China is a strategic move to access a large market, but it also introduces risks related to intellectual property and regulatory compliance, which are common challenges for companies operating in China.

Management Changes

Legal Proceedings

• The company is involved in a lawsuit filed by Sarah Veltz, alleging unpaid wages and sexual harassment.
• The company is engaged in settlement discussions with the Employment Development Department (EDD) of the State of California regarding the classification of certain workers.

Related Party Transactions

• The company has a consulting agreement with U.S. Asian Consulting Group, LLC, whose members are shareholders in the company.
• The company has a joint venture agreement with Wider Come Limited, a related party, for the development and distribution of its Gen-2 devices in China.
• The company has lease agreements with IIcom Strategic Inc., controlled by the company's Chief Executive Officer.

Stakeholder Impact

• Shareholders are impacted by the company's ongoing losses and the need for additional capital raises.
• Employees are impacted by the company's financial challenges and the need to implement new financial controls.
• Customers are impacted by the company's efforts to obtain regulatory approvals and commercialize its products.
• Suppliers are impacted by the company's financial challenges and its ability to pay for goods and services.
• Creditors are impacted by the company's financial challenges and its ability to repay its debts.

Next Steps

• The company plans to continue the ongoing and planned preclinical and clinical development of its products.
• The company will review and analyze the value of amending its previous 510(k) Application for anxiety and insomnia in accordance with the FDA.
• The company intends to arrange for an outsourced sales, marketing and distribution model and scale up external manufacturing capabilities to commercialize any product candidate for which it may obtain regulatory approval and intend to commercialize.
• The company will maintain, expand and protect its intellectual property portfolio.
• The company plans to engage additional clinical, scientific, manufacturing and controls personnel.
• The company will add additional information systems including personnel to support its product development.
• The company plans to schedule additional pilot trials and/or pivotal trials for the new Gen-3 device for anxiety and insomnia in the United States and China beginning in the fourth quarter of 2024.

Key Dates

Keywords

neurostimulation, mental health, FDA approval, medical device, clinical trials, joint venture, China, Nasdaq, regulatory approval, anxiety, insomnia, depression, virtual clinic, stock offering, financial results